《Embo Molecular Medicine》雜志的最新年發文量為112篇。
這表明該刊在每年都會精選并發表一定數量的高質量文章，以保持其在醫學：研究與實驗領域的學術影響力。
該刊聚焦于醫學-醫學：研究與實驗領域的前沿研究，致力于推動該領域新技術和新知識的傳播與應用。同時它積極鼓勵研究人員詳細發表其高質量的實驗研究和理論成果。
該刊的平均審稿周期約為 偏慢,4-8周 。
Embo Molecular Medicine 雜志發文統計
文章名稱引用次數
- Inflammasomes in neuroinflammatory and neurodegenerative diseases80
- Tranilast directly targets NLRP3 to treat inflammasome-driven diseases62
- The role of the microbiome in NAFLD and NASH61
- A versatile drug delivery system targeting senescent cells41
- G-quadruplex-binding small molecules ameliorate C9orf72 FTD/ALS pathology in vitro and in vivo40
- Reprogramming of basic metabolic pathways in microbial sepsis: therapeutic targets at last?36
- mtDNA heteroplasmy level and copy number indicate disease burden in m.3243A > G mitochondrial disease32
- Targeting senescent cells in translational medicine31
- Functional systemic CD4 immunity is required for clinical responses to PD-L1/PD-1 blockade therapy31
- Amyloid blood biomarker detects Alzheimer's disease31
國家/地區發文量
- USA160
- GERMANY (FED REP GER)114
- England98
- France61
- Spain54
- Italy53
- CHINA MAINLAND49
- Switzerland35
- Sweden34
- Canada32
